MedTrace Logo

Study on High-risk MDS Patients Based on RNA-seq Technology

NCT03903055 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2019-04-22

No results posted yet for this study

Summary

MDS is a group of malignant cloned blood diseases that originated from hematopoietic stem cells(HSC) or CD34 + progenitor cells and are still incurable. Its main characteristics are the increase of primitive cells in the bone marrow accompanied by a series or multiple developmental abnormalities(pathological hematopoiesis), the reduction of peripheral blood cells, the high risk of conversion to acute myeloid leukemia(AML), and once converted to leukemia, the treatment prognosis is very poor.The bone marrow cells of MDS patients were deeply sequenced by RNA-Seq method. Through differential gene expression analysis, different genes related to the onset and evolution of MDS were selected and their expression levels were analyzed in different subtype MDS patients. To study its significance in clinical classification, prognosis assessment and early intervention treatment, establish a new standard for clinical classification and prognosis evaluation based on genomic classification, clarify early intervention or precise treatment schemes, and significantly prolong the survival of patients, Improving the quality of life.

Conditions

Interventions

DIAGNOSTIC_TEST

MDS group

patients diagnosed as MDS with high risk，aged 18-80，men/wemen

Sponsors & Collaborators

  • Zhejiang Provincial Hospital of TCM

    lead OTHER

Principal Investigators

  • lin s yun, doctor · zjhtcm

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2021-12-31
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03903055 on ClinicalTrials.gov